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The etiology of reticular macular disease (RMD), a sub-phenotype of age-related macular degeneration 
(AMD), is controversial and has not been clarified. RMD is suspected to be a multifactorial, complex disease 
with genetic, environmental, and systemic factors playing an important role in its origin. Findings from 
combinations of different imaging modalities suggest that the pattern that characterizes this condition is 
associated with an alteration of the choriocapillaris blood flow. If the choroid is indeed affected in RMD, the 
possible linkage with inflammatory or other systemic diseases could be better supported. 
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INTRODUCTION  
Age-related macular degeneration (AMD) is a degenerative 
disease of the macula that results in loss of central vision and is 
the leading cause of adult blindness in industrialized countries 
[1]. Late-stage AMD may occur in two different forms: 
neovascular AMD, also known as choroidal neovascularization 
(CNV) or “wet AMD,” and geographic atrophy (GA), also known 
as late-stage “dry” AMD. The Eye Disease Prevalence Research 
Group has studied AMD prevalence in people over 40 years old. 
According to this group, the prevalence for both forms of late-
stage AMD is 1.47% in the United States, affecting 1.75 million 
people. They estimate a projected affected population of 3 
million people by 2020 [2]. While there are treatments 
available for wet AMD, there has been no proven effective 
treatment for GA. The only treatment option currently available 
for early AMD is antioxidant vitamin therapy, which shows a 
trend to benefit for prevention of GA per the Age-Related Eye 
Disease Study [3]. Thus, there is a need to better characterize 
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Drusen, which are localized deposits of extracellular material 
concentrated in the macula under the retinal pigment 
epithelium (RPE), have an established link with AMD. Recently, 
reticular pseudodrusen (RPD) have been described and 
associated with progression to late-stage AMD, especially CNV 
[4, 5]. RPD were first described in 1990 as a peculiar yellowish 
pattern in the macula of patients with AMD. Because their 
visibility was enhanced by the use of blue light, they were 
described as “les pseudodrusen bleus” [6]. Since then, 
numerous imaging modalities have been used to investigate 
this pattern. 
Using color fundus photographs, Klein et al. identified an ill-
defined network of broad, interlacing yellowish lesions 
occurring mainly in the outer macula and, based on their 
characteristic appearance, made these a separate entity 
(“reticular drusen”) in the Wisconsin Age-Related Maculopathy 
Grading System [7]. These were considered a type of drusen 
until Arnold et al. published a study on RPD that included a 
histopathological analysis of these lesions, which demonstrated 
a significant loss of the middle choroidal layer of small vessels 
and increased spacing between the large choroidal veins. This 
led to the hypothesis that fibrotic replacement of the choroidal 
stroma and loss of vascularity were responsible for the 
development of RPD, and RPD were proposed as a marker for 
choroidal ischemia [8]. 
Advances in imaging technology, particularly scanning laser 
ophthalmoscopy (SLO), have led to improved imaging and 
visualization of RPD. Unlike soft drusen, these lesions were 
observed to be hypofluorescent in the mid-to-late phases of 
indocyanine green angiography (ICGA) [9], with well-defined 
reticular patterns visualized with autofluorescence (AF) imaging 
[10]. Smith et al. demonstrated the characteristic appearances 
of reticular macular disease (RMD) using various imaging 
modalities, including SLO imaging (see Figure 1). They 
demonstrated spatial correspondence of individual lesions 
between imaging modalities, with the total areas of the macula 
involved either largely overlapping or falling within one 
another, suggesting that a single disease is responsible for each 
of these presentations [11]. The term “reticular macular disease 
(RMD)” includes RPD identified in color fundus photography or 
a reticular pattern seen in SLO, or both [11]. 
Klein and colleagues reported an overall RPD prevalence of 
0.7% in the general population and a 15-year cumulative 
incidence of 3.0% in a population aged 43 to 86 years at 
baseline [12]. Furthermore, they reported a high 15-year 
cumulative incidence of late AMD (43% and 46% in right and 
left eyes, respectively) and a 54% poorer survival rate in those 
with RPD at baseline. A large epidemiologic study reported 
female gender as a major risk factor for RPD (OR = 2.59) and a 
possible association between RPD and systemic diseases [12]. 
In addition, the prevalence of RMD in GA has been reported to 
be as high as 62% [13], and a large prospective study 
demonstrated that, while RMD occurs in only 7-8% of patients 
with AMD overall [14], RMD was present in around 30% of 
patients with CNV, with double the risk of progression to CNV 
in the fellow eye when the CNV was unilateral [4]. 
Different genetic loci have been identified and associated with 
an increased risk for AMD progression. Through genome-wide 
scanning and the candidate gene approach, complement factor 
H (CFH [Y402H, rs1061170]) on the chromosome 1q32 locus is 
known to be a risk haplotype-tagging variant for AMD [15]. 
Another genetic locus identified was the age-related 
maculopathy susceptibility gene (ARMS2 [A69S, rs10490924]) 
on chromosome 10q26 [16-18]. Based on preliminary genetic 
results, RMD appears to be highly associated with the ARMS2 
risk allele, whereas the CFH risk variant is not associated with 
RMD [19]. 
From these recent discoveries, we suspect that RMD is a 
multifactorial, complex disease, with genetic, environmental, 
and systemic (inflammatory or vascular) factors playing an 








Figure 1. Classic presentation of RMD in fundus 
photography identified as yellow or light interlacing 
networks ranging from 125 to 250 microns in width in 
color (first image) and red free (second image) images 
[8]. Reticular AF pattern, hypoautofluorescent lesions 
against a background of elevated AF (third image) [11, 
14]. Reticular IR pattern, hyporeflectant lesions against a 
background of hyperreflectance (fourth image) [11]. 
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HYPOTHESIS 
We postulate that the reticular pattern identified as RMD in 
different imaging modalities is related to an alteration in 
choriocapillaris blood flow. Indeed, many multimodal imaging 
studies have suggested this etiology [11, 20, 21]. This 
hypothesis is conceived from the experience of our research 
group with patients that present with RMD and our review of 
other groups’ studies. 
 
DISCUSSION 
We support our hypothesis by relying on imaging findings 
reported in studies that enabled detailed characterization of 
retinal layers and localized a possible origin of RMD. The use of 
optical coherence tomography (OCT) has allowed for better 
visualization of the choroid and retinal layers and increased our 
understanding of the important role of the choroid in RMD. 
Using en face OCT and precise image registration with AF, 
infrared (IR), and red free (RF) images, Sohrab et al. 
demonstrated that the arrangement and pattern of RPD are 
closely related to the choroidal stroma and the choroidal 
vasculature; reticular lesions followed the pattern of the 
underlying choroidal stroma on en face OCT and closely 
abutted larger choroidal vessels [20]. In another study using 
ICGA in addition to OCT, reticular areas appeared as 
hypofluorescent lesions adjacent to the large choroidal vessels 
[21]. Arnold et al. highlighted that the pattern seen in 
fluorescein angiography (FA) and ICGA is different in patients 
that have RMD and in those who have traditional drusen 
deposits. RMD is seen as distinctive groupings of 
hypofluorescent dots present in the mid-to-late phases of ICGA 
[9]. 
Rudolf et al. histologically described certain drusen-like lesions 
in AMD as “subretinal drusenoid deposits” [22]. Later studies 
[23-26] used OCT to describe discrete collections of 
interconnected hyperreflective deposit material above the RPE 
(unlike typical drusen, which are under the RPE), which were 
consistent with the original description of pseudodrusen, 
referring to them as “subretinal drusenoid deposits.” However, 
Querques et al. described corresponding areas of 
iso/hyperfluorescence on ICGA and IR adjacent to RPD lesions 
seen on OCT as subretinal deposits with inner segment/outer 
segment (IS/OS) disruption [21]. Similarly, Sohrab et al. used en 
face OCT to reveal subretinal hyperreflective deposits adjacent 
to RPD lesions on IR and overlying large choroidal vessels [20]. 
Given the close proximity to areas of hyperfluorescence, 
subretinal deposits may represent secondary mechanical or 
biologic disturbances in the overlying RPE and outer retina [21]. 
Zweifel et al. reported on “subretinal drusenoid deposits” in 
OCT and attempted to correlate imaging findings with 
postmortem histopathological reports demonstrating the 
deposition of drusenoid material between the RPE and IS/OS 
junction [23]. However, no clinical correlation with history of 
RMD in any imaging modality was provided [23]. In addition, 
histopathologic studies of eyes affected by AMD have shown 
degenerative changes in the choriocapillaris [28-31]. 
Angiography and other blood flow studies have also evidenced 
an impairment of choroidal circulation [27-30]. Hayreh 
concluded that the submacular choroid is more vulnerable to 
chronic ischemia than any other area of the posterior choroid 
[27]. Further histopathological analysis should include fresh eye 
samples with a diagnosis of RMD.  
We have previously hypothesized that there is an association 
between RMD and inflammatory and vascular damage of the 
choroid [5, 11]. The choroid contains high levels of elements 
that make up both the alternate and the classic complement 
pathways, including complement factor H (CFH), while in the 
RPE, low levels of these elements have been identified. The 
assembly of the membrane attack complex affects the choroid, 
suggesting that AMD pathogenesis involves local complement 
activation at the level of the choroid [21, 31]. The activation of 
the complement system produces an inflammatory process 
within the choroid, which may lead to atrophic vascular 
compromise and fibrous replacement and yield the 
characteristic appearance of RMD in RF, IR, and AF imaging. In 
addition, this fibrous replacement could explain the impaired 
filling in FA and ICGA imaging reported in patients with RMD, 
which is likely secondary to the blockage of fluorescence flow 
[6, 8, 11, 21].  
While the pathogenesis is still unclear, there is a reported 
association between RMD and systemic diseases, such as 
hypertension and angina, as well as an increased mortality rate 
independent of comorbidities [11, 12, 19]. In addition, the 
disproportionate number of females presenting with RMD may 
suggest a possible autoimmune origin, consistent with the 
extraordinarily high proportion of women at risk for 
autoimmune processes [12, 19]. On the other hand, it has also 
been suggested that there may be an association between 
AMD and hormonal changes characteristic of menopause, 
suggesting that low serum levels of estrogen may play an 
important role in the development of AMD, which led Snow et 
al. to propose that longer estrogen exposure may be a 
protective factor against this condition [32]. Thus, if 
cardiovascular disease and RMD are related, males (who die 
younger of cardiovascular disease) may be underrepresented in 
the older population who are identified with the RMD subtype 
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Genetic factors may also play a considerable role in the 
pathogenesis of RMD, with one study associating the ARMS2 
gene with end-stage AMD as well as RMD [33]. However, the 
pathogenesis and function of the ARMS2 allele remains 
unknown. Exploration of the genotype/phenotype correlation 
between ARMS2 and RMD may clarify the significance of the 
allele and its role in disease. Further speculation must await 
more data on the function of the ARMS2 gene and its specific 
role in AMD [20].  
Currently, phase 2/3 trials are underway for MC-1101 
(hydralazine, MacuClear, Inc.) to treat dry AMD [34]. This drug 
has been shown in animal studies and preclinical trials to 
increase choroidal blood flow and remove physiologic waste 
from the RPE, Bruch’s membrane, and photoreceptor cells. 
Since RMD is a high-risk AMD phenotype, these trials, if 
successful, could further support our theory that altered 
choroidal blood flow is mainly responsible for RMD. 
 
CONCLUSION 
Imaging analysis, histopathological reports, and the possible 
association between RMD and systemic diseases support our 
hypothesis that blood flow disturbance in the choroid is 
involved in the pathogenesis of RMD. Future studies should 
further investigate the association of RMD with systemic and 
inflammatory diseases, as well as histopathological 
examinations and imaging analysis of the same study eye, to to 
better elucidate the origin and pathophysiology of RMD. 
DISCLOSURE 
The authors report no conflicts of interest in this work. This study has 
been supported by unrestricted funds from Research to Prevent 
Blindness (RTS), an individual investigator research award from the 
Foundation Fighting Blindness (RTS), and the Kaplen Foundation (SB). 
 
REFERENCES 
1. Hyman L. Epidemiology of eye disease in the elderly. Eye. 
1987;1(2):330-41. 
2. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de 
Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence 
Research Group. Prevalence of age-related macular degeneration in 
the United States. Arch Ophthalmol. 2004 Apr;122(4):564-72. 
Erratum in: Arch Ophthalmol. 2011 Sep;129(9):1188. PMID: 
15078675. 
3. Age-Related Eye Disease Study Research Group. A randomized, 
placebo-controlled, clinical trial of high-dose supplementation with 
vitamins C and E, beta carotene, and zinc for age-related macular 
degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 
2001;119(10):1417-36. 
4. Cohen SY, Dubois L, Tadayoni R, Delahaye-Mazza C, Debibie C, 
Quentel G. Prevalence of reticular pseudodrusen in age-related 
macular degeneration with newly diagnosed choroidal 
neovascularisation. Br J Ophthalmol. 2007 Mar;91(3):354-9. PMID: 
16973663. 
5. Pumariega NM, Smith RT, Sohrab MA, Letien V, Souied EH. A 
prospective study of reticular macular disease. Ophthalmology. 2011 
Aug;118(8):1619-25. 
6. Mimoun G, Soubrane G, Coscas G. [Macular drusen]. J Fr 
Ophtalmol. 1990;13(10):511-30. PMID: 2081842. 
7. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The 
Wisconsin age-related maculopathy grading system. Ophthalmology. 
1991 Jul;98(7):1128-34. PMID: 1843453. 
8. Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular 
pseudodrusen: A risk factor in age-related maculopathy. Retina. 
1995;15(3):183-91. 
9. Arnold JJ, Quaranta M, Soubrane G, Sarks SH, Coscas G. 
Indocyanine green angiography of drusen. Am J Ophthalmol. 1997 
Sep;124(3):344-56. PMID: 9439360. 
10. Lois N, Owens SL, Coco R, Hopkins J, Fitzke FW, Bird AC. Fundus 
autofluorescence in patients with age-related macular degeneration 
and high risk of visual loss. Am J Ophthalmol. 2002 Mar;133(3):341-9. 
PMID: 11860971. 
11. Smith RT, Sohrab MA, Busuioc M, Barile G. Reticular macular 
disease. Am J Ophthalmol. 2009 Nov;148(5):733-743.e2. PMID: 
19878758. 
12. Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BE. The 
epidemiology of retinal reticular drusen. Am J Ophthalmol. 2008 
Feb;145(2):317-26. 
13. Schmitz-Valckenberg S, Alten F, Steinberg JS, Jaffe GJ, 
Fleckenstein M, Mukesh BN, Hohman TC, Holz FG; Geographic 
Atrophy Progression (GAP) Study Group. Reticular drusen associated 
with geographic atrophy in age-related macular degeneration. Invest 
Ophthalmol Vis Sci. 2011 Aug 24;52(9):5009-15. PMID: 21498612. 
14. Smith RT, Chan JK, Busuioc M, Sivagnanavel V, Bird AC, Chong NV. 
Autofluorescence Characteristics of Early, Atrophic, and High-Risk 
Fellow Eyes in Age-Related Macular Degeneration. Invest Ophthalmol 
Vis Sci. 2006 Sep;47(12):5495-504. 
15. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning 
AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott 
J, Barnstable C, Hoh J. Complement factor H polymorphism in age-
related macular degeneration. Science. 2005 Apr 15;308(5720):385-9. 
PMID: 15761122. 
16. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, 
Meitinger T, Weber BHF. Hypothetical LOC387715 is a second major 
susceptibility gene for age-related macular degeneration, 
contributing independently of complement factor H to disease risk. 
Hum Mol Genet. 2005 Nov;14(21):3227-36. 
17. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin 
MB. Susceptibility genes for age-related maculopathy on 
chromosome 10q26. Am J Hum Genet. 2005 Sep;77(3):389-407. 
PMID: 16080115. 
18. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, 
Farrer LA. Complement factor H polymorphism and age-related 
macular degeneration. Science. 2005 Apr 15;308(5720):421-4. PMID: 
15761121. 
19. Smith RT, Merriam JE, Sohrab MA, Pumariega NM, Barile G, 
Blonska AM, Haans R, Madigan D, Allikmets R. Complement Factor H 




MEHDI Ophthalmology Journal 2012; Vol. 1, No 2  
 
 
41 IS RETICULAR MACULAR DISEASE A CHORIOCAPILLARIS PERFUSION PROBLEM? 
20. Sohrab MA, Smith RT, Salehi-Had H, Sadda SR, Fawzi AA. Image 
registration and multimodal imaging of reticular pseudodrusen. 
Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5743-8. PMID: 21693600. 
21. Querques G, Querques L, Forte R, Massamba N, Coscas F, Souied 
EH. Choroidal Changes Associated with Reticular Pseudodrusen. 
Invest Ophthalmol Vis Sci. 2012 Mar;53(3):1258-63. 
22. Rudolf M, Malek G, Messinger JD, Clark ME, Wang L, Curcio CA. 
Sub-retinal drusenoid deposits in human retina: organization and 
composition. Exp Eye Res. 2008 Nov;87(5):402-8. PMID: 18721807. 
23. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular 
pseudodrusen are subretinal drusenoid deposits. Ophthalmology. 
2010 Feb;117(2):303-12.e1. 
24. Zweifel SA, Imamura Y, Spaide TC, Fujiwara T, Spaide RF. 
Prevalence and significance of subretinal drusenoid deposits 
(reticular pseudodrusen) in age-related macular degeneration. 
Ophthalmology. 2010 Sep;117(9):1775-81. 
25. Spaide RF, Curcio CA. Drusen characterization with multimodal 
imaging. Retina. 2010 Oct;30(9):1441-54. 
26. Schmitz-Valckenberg S, Steinberg JS, Fleckenstein M, Visvalingam 
S, Brinkmann CK, Holz FG. Combined confocal scanning laser 
ophthalmoscopy and spectral-domain optical coherence tomography 
imaging of reticular drusen associated with age-related macular 
degeneration. Ophthalmology. 2010 Jun;117(6):1169-76. 
27. Hayreh SS. Posterior ciliary artery circulation in health and 
disease: the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2004 
Mar;45(3):749-57. 
28. Hayreh SS. Controversies on submacular choroidal circulation. 
Ophthalmologica. 1981;183(1):11-9. PMID: 7312289. 
29. Hayreh SS. Macular lesions secondary to choroidal vascular 
disorders. Indian J Ophthalmol. 1983 May;31(3):158-64. PMID: 
6676205. 
30. Foos RY, Trese MT. Chorioretinal juncture. Vascularization of 
Bruch's membrane in peripheral fundus. Arch Ophthalmol. 1982 
Sep;100(9):1492-503. PMID: 7115180. 
31. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT. 
Curletti CR, Hancox LS, Johnson LV. The pivotal role of the 
complement system in aging and age-related macular degeneration: 
hypothesis re-visited. Prog Retin Eye Res. 2010;29(2):95-112. 
32. Snow KK, Cote J, Yang W, Davis NJ, Seddon JM. Association 
between reproductive and hormonal factors and age-related 
maculopathy in postmenopausal women. Am J Ophthalmol. 2002 
Dec;134(6):842-8. PMID: 12470752. 
33. Leveziel N, Puche N, Richard F, Somner JE, Zerbib J, Bastuji-Garin 
S, Cohen SY, Korobelnik JF, Sahel J, Soubrane G, Benlian P, Souied EH. 
Genotypic influences on severity of exudative age-related macular 
degeneration. Invest Ophthalmol Vis Sci. 2010 May;51(5):2620-5. 
PMID: 20042647. 
34. Chiou G. Is dry AMD treatable? A new ophthalmic solution may 
halt disease progression. Retina Today. 2012(May/June):69-71. 
 
  
 
